New SP plants in Singapore
US pharmaceutical giant Schering-Plough has opened two drug manufacturing plants in Singapore worth Sing$320m (€231m). A sterile facility with investments worth Sing$180m (€122m) will be used for the freeze-drying, finishing and packaging of leading drugs for the treatment of hepatitis C and Crohn's disease. Another Sing$140m (€109m) facility will manufacture Zetia tablets, a new drug for cholesterol management.